Home » News » 12/05 » Schwarz Pharma gets PD go ahead

Schwarz Pharma gets PD go ahead

Date published: 16/12/2005

European regulators have given their backing to Schwarz Pharma's Parkinson's disease (PD) patch Neupro. After the decision by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) the firm will be able to market the rotigotine transdermal patch in all 25 European Union countries.

Schwarz CEO Patrick Schwarz-Schutte said: "This positive opinion is a milestone for our company. We are delivering on our strategy ? to develop and market innovative drugs in the areas of neurology and urology. "We are now getting ready for the market introduction of Neupro within Europe in the first half of 2006."

Dr Iris Loew-Friedrich, member of the executive board, explained how the drug worked. She said: "Transdermal administration of a dopamine agonist offers a promising option for patients suffering from early Parkinson's disease.

"Rotigotine, a new chemical entity, is combined with an innovative formulation technology, the first Parkinson's patch, to offer patients good symptom control over twenty-four hours." PD is thought to affect around four million people worldwide.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.